These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 32386720)

  • 41. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    Nielsen-Saines K; Watts DH; Veloso VG; Bryson YJ; Joao EC; Pilotto JH; Gray G; Theron G; Santos B; Fonseca R; Kreitchmann R; Pinto J; Mussi-Pinhata MM; Ceriotto M; Machado D; Bethel J; Morgado MG; Dickover R; Camarca M; Mirochnick M; Siberry G; Grinsztejn B; Moreira RI; Bastos FI; Xu J; Moye J; Mofenson LM;
    N Engl J Med; 2012 Jun; 366(25):2368-79. PubMed ID: 22716975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France.
    Kherabi Y; de Castro N; Sellier PO; Hamet G; Brun A; Méchaï F; Joly V; Yazdanpanah Y; Molina JM
    J Acquir Immune Defic Syndr; 2022 Sep; 91(1):85-90. PubMed ID: 35616997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
    Blonk MI; Colbers AP; Hidalgo-Tenorio C; Kabeya K; Weizsäcker K; Haberl AE; Moltó J; Hawkins DA; van der Ende ME; Gingelmaier A; Taylor GP; Ivanovic J; Giaquinto C; Burger DM; ;
    Clin Infect Dis; 2015 Sep; 61(5):809-16. PubMed ID: 25944344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
    Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
    Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
    Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA
    AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.
    Rahangdale L; Cates J; Potter J; Badell ML; Seidman D; Miller ES; Coleman JS; Lazenby GB; Levison J; Short WR; Yawetz S; Ciaranello A; Livingston E; Duthely L; Rimawi BH; Anderson JR; Stringer EM;
    Am J Obstet Gynecol; 2016 Mar; 214(3):385.e1-7. PubMed ID: 26928154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
    van Lunzen J; Maggiolo F; Arribas JR; Rakhmanova A; Yeni P; Young B; Rockstroh JK; Almond S; Song I; Brothers C; Min S
    Lancet Infect Dis; 2012 Feb; 12(2):111-8. PubMed ID: 22018760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
    Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
    Lallemant M; Amzal B; Sripan P; Urien S; Cressey TR; Ngo-Giang-Huong N; Klinbuayaem V; Rawangban B; Sabsanong P; Siriwachirachai T; Jarupanich T; Kanjanavikai P; Wanasiri P; Koetsawang S; Jourdain G; Le Coeur S;
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):313-322. PubMed ID: 32205720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
    Cooper DA; Heera J; Ive P; Botes M; Dejesus E; Burnside R; Clumeck N; Walmsley S; Lazzarin A; Mukwaya G; Saag M; van Der Ryst E
    AIDS; 2014 Mar; 28(5):717-25. PubMed ID: 24983542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
    Harrington BJ; DiPrete BL; Jumbe AN; Ngongondo M; Limarzi L; Wallie SD; Chagomerana MB; Hosseinipour MC;
    Trop Med Int Health; 2019 Oct; 24(10):1221-1228. PubMed ID: 31381233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
    Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Campbell H; Strohmaier KM; Wan H; Danovich RM; Teppler H;
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):350-6. PubMed ID: 19648823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.